Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.

It has been postulated that the use of highly active antiretroviral therapy (HAART) would reduce the occurrence of human immunodeficiency virus (HIV)-associated weight loss and wasting. To test this assumption, we evaluated, by means of longitudinal analysis, a prospective cohort of 469 HIV-infected individuals enrolled in a study of the impact of HIV on nutrition. Overall, 156 individuals in the cohort (33.5%) met at least 1 of these definitions of wasting. Furthermore, 58% of the cohort (289 patients) lost >1.5 kg of weight in a 6-month period between any 2 study visits. More than 50% of the cohort was receiving HAART at the time that they met 1 of the definitions of wasting; with regard to the occurrence of wasting; no differences were related to therapy.

[1]  J. Ward,et al.  Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[2]  F. Carrat,et al.  Effect of indinavir on HIV‐related wasting , 1998, AIDS.

[3]  D. Spiegelman,et al.  The effect of protease inhibitors on weight and body composition in HIV‐infected patients , 1998, AIDS.

[4]  J. Papadimitriou,et al.  HIV-1-associated nephropathy and response to highly-active antiretroviral therapy , 1998, The Lancet.

[5]  B Clotet,et al.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.

[6]  C. Gibert,et al.  Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[7]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[8]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[9]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[10]  P. Singhal,et al.  HIV-1 gp160 envelope protein modulates proliferation and apoptosis in mesangial cells. , 1997, Nephron.

[11]  P. Kimmel,et al.  Captopril and renal survival in patients with human immunodeficiency virus nephropathy. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. , 1996, JAMA.

[13]  R. Salata,et al.  Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. , 1996, The American journal of medicine.

[14]  P. Kimmel,et al.  Apoptosis in human immunodeficiency virus-associated nephropathy. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  T. Greenough,et al.  High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.

[16]  E. Friedman,et al.  Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. , 1995, American journal of nephrology.

[17]  J. Rullán,et al.  HIV wasting syndrome in the United States , 1993, AIDS.

[18]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.